Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer.
When to stop watchful waiting and begin definitive treatment of African American patients explored in The Journal of Urology
A new study published in The Journal of Urology® revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.
Patients with metabolic syndrome (MetS) are at elevated risk of bladder cancer, according to a new study.
In a hospital-based case-control study, researchers led by Maurizio Montella, MD, of Istituto Tumori “Fondazione Pascale IRCCS,” Naples, Italy, compared 690 patients with incident urothelial carcinoma of the bladder (UCB) and 665 cancer-free matched control patients.
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibition with olaparib.
A new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer.
Cigarette smoking is associated with an increased risk of overactive bladder (OAB) symptoms in women, according to a new British study.
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.
Kidney stone disease is a complex disorder with a strong genetic component. We conducted a genome-wide association study of 28.3 million sequence variants detected through whole-genome sequencing of 2,636 Icelanders that were imputed into 5,419 kidney stone cases, including 2,172 cases with a history of recurrent kidney stones, and 279,870 controls.
For years, research on prostate cancer has sought an approach to screening that is more individualized than a one-size-fits-all measurement of the level of prostate-specific antigen in a man’s blood. These efforts are now paying off.
Smoking is a risk factor for biochemical recurrence of prostate cancer (PCa) following radical prostatectomy (RP), new study findings suggest.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.